BackgroundBecause lymphatic filariasis (LF) elimination efforts are hampered by a dearth of economic information about the cost of mass drug administration (MDA) programs (using either albendazole with diethylcarbamazine [DEC] or albendazole with ivermectin), a multicenter study was undertaken to determine the costs of MDA programs to interrupt transmission of infection with LF. Such results are particularly important because LF programs have the necessary diagnostic and treatment tools to eliminate the disease as a public health problem globally, and already by 2006, the Global Programme to Eliminate LF had initiated treatment programs covering over 400 million of the 1.3 billion people at risk.Methodology/Principal FindingsTo obtain annual costs to carry out the MDA strategy, researchers from seven countries developed and followed a common cost analysis protocol designed to estimate 1) the total annual cost of the LF program, 2) the average cost per person treated, and 3) the relative contributions of the endemic countries and the external partners. Costs per person treated ranged from $0.06 to $2.23. Principal reasons for the variation were 1) the age (newness) of the MDA program, 2) the use of volunteers, and 3) the size of the population treated. Substantial contributions by governments were documented – generally 60%–90% of program operation costs, excluding costs of donated medications.Conclusions/SignificanceMDA for LF elimination is comparatively inexpensive in relation to most other public health programs. Governments and communities make the predominant financial contributions to actual MDA implementation, not counting the cost of the drugs themselves. The results highlight the impact of the use of volunteers on program costs and provide specific cost data for 7 different countries that can be used as a basis both for modifying current programs and for developing new ones.

Background: Mass drug administration (MDA) has been one of the strategies endorsed by the World Health Assembly for lymphatic filariasis (LF) elimination. Many factors, however, affect the acceptability of the MDA in the Philippines with acceptability defined as the ingestion of drugs -diethylcarbamazine and albendazole during MDA. These drugs were mainly distributed in fixed sites and mopping up activities were conducted through house-to-house visits to increase treatment coverage. The aim of conducting the study was to determine the MDA acceptance rate among a population endemic for LF, and the factors associated with MDA acceptance.

BackgroundPraziquantel at 40 mg/kg in a single dose is the WHO recommended treatment for all forms of schistosomiasis, but 60 mg/kg is also deployed nationally.Methodology/Principal FindingsFour trial sites in the Philippines, Mauritania, Tanzania and Brazil enrolled 856 patients using a common protocol, who were randomised to receive praziquantel 40 mg/kg (n = 428) or 60 mg/kg (n = 428). While the sites differed for transmission and infection intensities (highest in Tanzania and lowest in Mauritania), no bias or heterogeneity across sites was detected for the main efficacy outcomes. The primary efficacy analysis was the comparison of cure rates on Day 21 in the intent-to-treat population for the pooled data using a logistic model to calculate Odd Ratios allowing for baseline characteristics and study site. Both doses were highly effective: the Day 21 cure rates were 91.7% (86.6%–98% at individual sites) with 40 mg/kg and 92.8% (88%–97%) with 60 mg/kg. Secondary parameters were eggs reduction rates (ERR), change in intensity of infection and reinfection rates at 6 and 12 months. On Day 21 the pooled estimate of the ERR was 91% in both arms. The Hazard Ratio for reinfections was only significant in Brazil, and in favour of 60 mg/kg on the pooled estimate (40 mg/kg: 34.3%, 60 mg/kg: 23.9%, HR = 0.78, 95%CI = [0.63;0.96]). Analysis of safety could not distinguish between disease- and drug-related events. 666 patients (78%) reported 1327 adverse events (AE) 4 h post-dosing. The risk of having at least one AE was higher in the 60 than in the 40 mg/kg group (83% vs. 73%, p<0.001). At 24 h post-dosing, 456 patients (54%) had 918 AEs with no difference between arms. The most frequent AE was abdominal pain at both 4 h and 24 h (40% and 24%).ConclusionA higher dose of 60 mg/kg of praziquantel offers no significant efficacy advantage over standard 40 mg/kg for treating intestinal schistosomiasis caused by either S. mansoni or S. japonicum. The results of this study support WHO recommendation and should be used to inform policy decisions in the countries.Trial Registration Controlled-Trials.com ISRCTN29273316 ClinicalTrials.gov NCT00403611

SUMMARYA quasi-experimental design was used to test the hypothesis that there will be a significant improvement in both coastal resource management (CRM) and human reproductive health (RH) outcomes by delivering these services in an integrated manner as opposed to delivering either in isolation. The CRM, RH and integrated CRM+RH interventions were tested in three island municipalities of Palawan. Pre-project (2001) and post-project (2007) measurements of dependent variables were gathered via biophysical and community household surveys. Regression analyses indicate the CRM+RH intervention generated higher impacts on human and ecosystem health outcomes compared to the independent CRM and RH interventions. Improvements in coral and mangrove conditions are attributed to the effects of protective management by collaborating peoples’ organizations. The same institutions managed RH activities that enabled contraceptive access and a significant decrease in the average number of children born to women in the study area. Other trends showing a significant reduction in income-poverty among young adults infer added value. To ensure long term sustainability of CRM gains and prevent over-use of coastal resources, integrated forms of management that engage communities in the simultaneous delivery of conservation and family planning services are needed.

Aim:  To determine the risk factors of symptomatic osteoarthritis (OA) of the knee.Methods:  Two hundred and thirty‐nine cases of symptomatic OA of the knee (ACR Criteria for OA 1986) with radiographic OA (Kellgren‐Lawrence I or more) taken from a rheumatology outpatient clinic were compared to 279 controls without radiographic (Kellgren‐Lawrence 0) OA taken from general internal medicine outpatient clinic at the same hospital. Independent variables to be assessed were age, sex, ethnic group, body mass index (BMI), education, marital status, parity, smoking, and history of acute trauma, hysterectomy, anatomical abnormality of knee, diabetes mellitus, and uric acid levels. Multiple logistic regression analysis was done to assess the independent risk factors.Results:  After going through the steps of multiple logistic regressions analysis, the results were: symptomatic cases compared to controls: age > 50 (OR: 1.86, 95% CI = 1.78–2.82), being female (OR: 2.08, 95% CI = 1.35–3.50), BMI > 25 units (OR: 3.28, 95% CI = 2.20–4.89), elementary education (OR: 0.29, 95% CI = 0.14–0.61) and genu valgus (OR: 4.07, 95% CI = 2.43–7.93). For the female subset of symptomatic cases compared with controls: age > 50 (OR: 9.34, 95% CI = 4.77–18.24), BMI > 25 units (OR: 5.27, 95% CI = 2.85–9.73) and genu valgus (OR: 13.64, 95% CI = 4.58–41.44).Conclusions:  Age > 50, being female, BMI > 25 units and genu valgus, may be the risk factors for symptomatic OA of the knee.